The Daily Papule

Meeting abstracts

BAD 2026

British Association of Dermatologists · Manchester, 30 June – 2 July 2026

639 abstracts, published in BJD on 26 June 2026.

  1. BG03

    Atopic eczema in older adults: findings from the UK-Irish Atopic eczema Systemic therapy Register (A-STAR)

    Gawkrodger DJ, Tsoi MF, … senior author Flohr C

  2. BG07

    Three cases of biologic-associated interstitial lung disease

    Bowe S, Kiely J, … senior author Bourke J

  3. BH06

    Monitoring of nail psoriasis with optical coherence tomography under treatment with tildrakizumab for 52 weeks

    Hobelsberger S, Schmirler S, … senior author Beissert S

  4. BI01

    Toxic epidermal necrolysis in advanced HIV: a case report and therapeutic considerations

    Sexton F, Morrissey P, … senior author Quinn G

  5. BI02

    Toxic epidermal necrolysis in an immunosuppressed patient on tumour necrosis factor-α inhibition: a role for interleukin-6 targeting

    Lim S, Guinan T, Hindle E

  6. BI03

    An out-of-place mucosal virus causing cutaneous crisis: a rare case of disseminated human papillomavirus-6 infection during upadacitinib therapy for atopic dermatitis

    Moon E, Shanshal M

  7. BI09

    Risk of skin cancer in solid organ transplant recipients prescribed biologics for psoriasis

    Ray R, Chin N, Yu J

  8. BI19

    Risk management of infectious diseases in dermatology: a comprehensive clinical framework for patients being managed with immunosuppressants and biological agents

    Ra A, Foulkes A, Young H

  9. BI35

    Skin-focused safety measures in upadacitinib-treated inflammatory bowel disease: a service evaluation

    Kuladeva D, Zhen Yam AI, Paul Seenan J

  10. BI40

    Prevalence of Strongyloides seropositivity in patients with eczema requiring biologic therapy in a UK multisite trust

    Ngai A, Cunningham M, … senior author Mehrtens S

  11. BI43

    A high-risk squamous cell carcinoma developing in a patient with eczema treated with upadacitinib

    Murphy L, McCafferty B, … senior author McKenna D

  12. BI44

    Hepatitis B reactivation risk perception and viral screening practices among Irish dermatologists

    Fagan N, Hughes R

  13. BI45

    A double-edged sword: life-threatening adverse effects of 6-mercaptopurine

    Shaw R, Weatherhead S, Meggitt S

  14. BI46

    Acquired haemophilia A following biologic therapy for dermatological conditions: a systematic review of published case reports

    Alomar A, Al Lawati A, Almulla L

  15. GD12

    Tinea indotineae complicating and potentially propagated by psoriasis

    Illango A, Montgomery R, … senior author Muinonen-Martin A

  16. LY02

    Dupilumab use in atopic dermatitis when cutaneous lymphoma is suspected: consensus recommendations from the EORTC Cutaneous Lymphoma Tumour Group

    Calvão J, Gonçalo M, … senior author Guenova E

  17. LY25

    Primary cutaneous diffuse large B-cell lymphoma, leg type presenting as rapidly enlarging nodules on the calf

    Butt S, Rashid S

  18. O04

    Using biologic therapies as first-line systemic treatment for psoriasis: a cohort study following the target trial emulation framework from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

    Phan DB, Laws P, … senior author Yiu Z

  19. O05

    Drug survival of dupilumab, methotrexate and ciclosporin in patients with atopic eczema: results from the UK-Irish Atopic eczema Systemic TherApy Register (A-STAR)

    Gribaleva E, Tsoi MF, … senior author Flohr C

  20. O09

    Drug reaction with eosinophilia and systemic symptoms (DRESS) eosinophil transcriptomes show distinct interleukin-5 and interleukin-3 regulation compared with atopic dermatitis and asthma

    Dezoteux F, Clayton K, … senior author Ardern-Jones MR

  21. O10

    Risk factors for incident and recurrent erythrodermic psoriasis: cohort analyses from the British Association of Dermatologists Biologics and Immunomodulators Register

    Al-Janabi A, Alabas O, … senior author Warren RB

  22. O11

    Model-informed precision dosing of biologic therapies in psoriasis: development, validation and clinical translation

    Wei R, Thomas C, … senior author Mahil S

  23. P012

    Therapeutic equivalence of an omalizumab biosimilar (ADL-018) to the European Union-approved reference omalizumab in chronic spontaneous urticaria

    Delgado M, Rivas A, … senior author Vadday K

  24. P016

    A case of metastatic Crohn disease successfully treated with upadacitinib

    Partridge L, Jaulim SZ

  25. P024

    Paradoxical exacerbation of Sweet-like dermatosis following tumour necrosis factor inhibition unmasking VEXAS syndrome

    Ali S, Wolinska A, … senior author Kearney N

  26. P030

    A rash decision: refractory erythroderma as an atypical presentation of hypocomplementaemic urticarial vasculitis

    Victory L, Fagan N, … senior author Tobin AM

  27. P031

    Granulomatous eruptions in patients treated with dupilumab

    Allotey B, Pattle S, Sergeant A

  28. P033

    Toxic epidermal necrolysis-like lupus treated with etanercept

    Ralph J, Gaffney A, … senior author Alsharqi A

  29. P038

    Guselkumab for pembrolizumab-induced psoriasis in a patient with metastatic melanoma

    Conlon O, Herlihy M, … senior author O’Kane, Eilis Ni Chinneide, Helen Barrett and Adrian Murphy M

  30. P040

    An aggressive multisystem presentation of bowel-associated dermatosis–arthritis syndrome

    Ibrahim L, Zaman M

  31. P041

    Acral cutaneous Mycobacterium marinum infection in an adolescent receiving adalimumab

    Conlon O, Kiely L, … senior author Dhonncha EN

  32. P055

    Real-world experience using guselkumab for pyoderma gangrenosum: rapid responses in three patients

    Dalton C, Eakins S, … senior author Hughes R

  33. P056

    Systemic signs of rheumatoid activity

    Beatty P, Howard-James C, Gilhooley E

  34. P070

    Setting up a Nurse-Led Atopic Dermatitis (NuLAD) service

    Qasem N, Sandhu S, … senior author Fremlin G

  35. P103

    Infliximab treatment in patients with hidradenitis suppurativa after failure of conventional therapy

    Kreuser AL, Hampton P, … senior author Jobling K

  36. P104

    Optimizing dupilumab initiation through standardized prescreening: a quality improvement project

    Mackender E, Petrou IA, Ali M

  37. P108

    Biologics polyclinic is an efficient and safe way to support a biologics service

    Housam N, Whitley H, Levell NJ

  38. P110

    From survey to service: launching Scotland’s first national hidradenitis suppurativa virtual multidisciplinary team meeting

    Kuladeva D, Nguyen V, … senior author Honan A

  39. P115

    Differential risk of incident psoriatic arthritis across immunomodulator classes used for psoriasis: a prospective cohort study

    Al-Janabi A, Alabas O, … senior author Warren RB

  40. P116

    Differential risk of incident and recurrent erythrodermic psoriasis in patients receiving systemic therapies: cohort analyses from the British Association of Dermatologists Biologics and Immunomodulators Register

    Al-Janabi A, Alabas O, … senior author Warren RB

  41. P122

    Real-world experience of tildrakizumab from a specialist dermatology department at a district hospital in the UK

    Barfoot M, Francis C, … senior author Schultz A

  42. P123

    The association of (hyper)eosinophilia with atopic dermatitis severity and treatment response: evidence from the UK-Irish Atopic eczema Systemic TherApy Register (A-STAR)

    Dezoteux F, Tsoi MF, … senior author Ardern-Jones MR

  43. P124

    Real-world effectiveness of guselkumab in moderate-to-severe plaque psoriasis with high-impact-site involvement: evidence from the British Association of Dermatologists Biologics and Immunomodulators Register

    Lloyd-Lavery A, El-Heis S, … senior author Jones H

  44. P126

    Treatment journey in patients with atopic dermatitis on abrocitinib: real-world evidence from the DREAM TO TREAT AD (D2T AD) Consortium

    Prieto-Merino D, Gribaleva E, … senior author Flohr C

  45. P128

    Clinical and immunological effects of treatment with S2K guidelines (2020) on 72 patients with pemphigus: a pre–post study

    Singh S, Chaudhary S

  46. P132

    Safety and effectiveness of tralokinumab treatment in adults with atopic dermatitis who previously discontinued dupilumab due to the adverse event conjunctivitis: 12-months real-world data from the TRACE study

    Armstrong AW, Rubin C, … senior author Thaçi D

  47. P133

    Improvements in sleep among people with atopic dermatitis: a systematic review of randomized clinical trial evidence and outcomes for biologic treatments

    Flohr C, Wan M, … senior author Watkins M

  48. P135

    Advanced therapies in pyoderma gangrenosum: insights from a UK dermatology centre

    Sebastian N, Lewis H, Fremlin G

  49. P139

    Real-world longitudinal rituximab use in pemphigus and pemphigoid: outcomes from a UK tertiary centre

    Wong V, Elhag S, … senior author Fremlin G

  50. P141

    Maintaining disease control on systemic immunomodulatory therapy for psoriasis: a systematic review and meta-analysis

    Ye W, Corbett M, … senior author Mahil S